Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 72, Issue , 2017, Pages 60-72

  Qiu, Xiaoyan ^a   Xiao, Xiong ^a   Li, Nan ^a   Li, Yuemin ^a  

^a SOUTHWEST UNIVERSITY   (China)

Author keywords

Brain disorders; Cancer; Cell reprogramming; Endometriosis; HDACi

Indexed keywords

4 PHENYLBUTYRIC ACID; BUTYRIC ACID; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE; ROMIDEPSIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; BRAIN DISEASE; BRAIN ISCHEMIA; CELL NUCLEUS TRANSPLANTATION; COGNITIVE DEFECT; COMBINATION DRUG THERAPY; CUTANEOUS T CELL LYMPHOMA; DEGENERATIVE DISEASE; DEPRESSION; DISEASE MODEL; DNA MODIFICATION; DRUG MECHANISM; ENDOMETRIOSIS; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; EVIDENCE BASED PRACTICE; FEAR; FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; GENE MUTATION; HISTONE ACETYLATION; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; MONOTHERAPY; NEOPLASM; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR REPROGRAMMING; PARKINSON DISEASE; REVIEW; RUBINSTEIN SYNDROME; SCHIZOPHRENIA; SOMATIC CELL THERAPY; SPINAL MUSCULAR ATROPHY; THERAPY EFFECT; TRANSCRIPTION REGULATION; ANIMAL; BRAIN DISEASES; ENZYMOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; BRAIN DISEASES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 84986880102     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2016.09.002     Document Type: Review

References (282)

1. Abel, T., Zukin, R.S., Epigenetic targets of hdac inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8:1 (2008), 57–64.
2. Alarcon, J.M., Malleret, G., Touzani, K., Vronskaya, S., Ishii, S., Kandel, E.R., Chromatin acetylation, memory, and ltp are impaired in cbp +/− mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42:6 (2004), 947–959.
3. Andreassi, C., Angelozzi, C., Tiziano, F.D., Vitali, T., De, V.E., Boninsegna, A., Villanova, M., Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 12 (2004), 59–65.
4. Avila, A.M., Burnett, B.G., Taye, A.A., Gabanella, F., Knight, M.A., Hartenstein, P., Cizman, Z., Di Prospero, N.A., Pellizzoni, L., Fischbeck, K.H., Sumner, C.J., Trichostatin a increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117:3 (2007), 659–671.
5. Bartholdi, D., Roelfsema, J.H., Papadia, F., Breuning, M.H., Niedrist, D., Hennekam, R.C., Schinzel, A., Peters, D.J.M., Genetic heterogeneity in rubinstein-taybi syndrome: delineation of the phenotype of the first patients carrying mutations in ep300. J. Med. Genet. 44:5 (2007), 327–333.
6. Bartolini, G., Orlandi, M.A., Ammar, K., Tonelli, R., Franzoni, M., Pession, A., Growth inhibition and proapoptotic activity induction by iif and valproic acid on ra-resistant leukemia cells. Anticancer Res. 28:1 (2008), 283–288.
7. Bates, G.P., Huntington's disease. Exploiting expression. Nature 413 (2001), 691–694.
8. Bates, E.A., Victor, M., Jones, A.K., Shi, Y., Hart, A.C., Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 26 (2006), 2830–2838.
9. Beebe, L.F., McIlfatrick, S.J., Nottle, M.B., Cytochalasin B and trichostatin A treatment postactivation improves in vitro development of porcine somatic cell nuclear transfer embryos. Cloning Stem Cells 11 (2009), 477–482.
10. Biacsi, R., Kumari, D., Usdin, K., SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome. PLoS Genet., 4, 2008, e1000017.
11. Bilang-Bleuel, A., Ulbricht, S., Chandramohan, Y., De Carli, S., Droste, S.K., Reul, J.M., Psychological stress increases histone H3 phosphorylation in adult dentate gyrus granule neurons: involvement in a glucocorticoid receptor-dependent behavioural response. Eur. J. Neurosci. 22 (2005), 1691–1700.
12. Blough, R.I., Petrij, F., Dauwerse, J.G., Milatovich-Cherry, A., Weiss, L., Saal, H.M., Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome. Am. J. Med. Genet. 90 (2000), 29–34.
13. Bodiford, A., Bodge, M., Talbott, M.S., Reddy, N.M., Profile of belinostat for the treatment of relapsed or refractory peripheral t-cell lymphoma. Oncotargets Ther. 7 (2014), 1971–1977.
14. Bourtchouladze, R., Lidge, R., Catapano, R., Stanley, J., Gossweiler, S., Romashko, D., Scott, R., Tully, T., A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 10518–10522.
15. Bowers, M.E., Xia, B., Carreiro, S., Ressler, K.J., The class I HDAC inhibitor RGFP963 enhances consolidation of cued fear extinction. Learn. Mem. 22:4 (2015), 225–231.
16. Brahe, C., Vitali, T., Tiziano, F.D., Angelozzi, C., Pinto, A.M., Borgo, F., Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. 13 (2005), 256–259.
17. Bredy, T.W., Wu, H., Crego, C., Zellhoefer, J., Sun, Y.E., Barad, M., Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn. Mem. 14:4 (2007), 268–276.
18. Brichta, L., Brichta, L., Hofmann, Y., Hahnen, E., Siebzehnrubl, F.A., Raschke, H., Blumcke, I., Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 12 (2003), 2481–2489.
19. Brichta, L., Holker, I., Karsten Haug, M.D., Thomas Klockgether, M.D., Wirth, B., In vivo activation of SMN, in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. 59 (2006), 970–975.
20. Buoncervello, M., Borghi, P., Romagnoli, G., Spadaro, F., Belardelli, F., Toschi, E., Gabriele, L., Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells. Neoplasia 14:9 (2012), 855–867.
21. Casey, D.E., Daniel, D.G., Wassef, A.A., Tracy, K.A., Wozniak, P., Sommerville, K.W., Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28 (2003), 182–192.
22. Cenik, B., Sephton, C.F., Dewey, C.M., Xian, X., Wei, S., Yu, K., Niu, W., Coppola, G., Coughlin, S.E., Lee, S.E., Dries, D.R., Almeida, S., Geschwind, D.H., Gao, F.B., Miller, B.L., Farese, R.V., Posner, B.A., Yu, G., Herz, J., Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J. Biol. Chem. 286:18 (2011), 16101–16108.
23. Chandramohan, Y., Droste, S.K., Arthur, J.S., Reul, J.M., The forced swimming-induced behavioural immobility response involves histone H3 phospho-acetylation and c-Fos induction in dentate gyrus granule neurons via activation of the N-methyl-Daspartate/extracellular signal-regulated kinase/mitogen- and stress activated kinase signalling pathway. Eur. J. Neurosci. 27 (2008), 2701–2713.
24. Chang, S.T., Yung, B.Y.M., Potentiation of sodium butyrate-induced apoptosis by vanadate in human promyelocytic leukemia cell line hl-60. Biochem. Biophys. Res. Commun. 221:3 (1996), 594–601.
25. Chang, J.G., Hsieh-Li, H.M., Jong, Y.J., Wang, N.M., Tsai, C.H., Li, H., Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 9808–9813.
26. Chen, Y., Sharma, R.P., Costa, R.H., Costa, E., Grayson, D.R., On the epigenetic regulation of the human reelin promoter. Nucleic Acids Res. 30 (2002), 2930–2939.
27. Chen, P.S., Peng, G.S., Li, G., Yang, S., Wu, X., Wang, C.C., Wilson, B., Lu, R.B., Gean, P.W., Chuang, D.M., Hong, J.S., Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol. Psychiatry 11 (2006), 1116–1125.
28. Chen, S.H., Wu, H.M., Ossola, B., Schendzielorz, N., Wilson, B.C., Chu, C.H., Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br. J. Pharmacol. 165:2 (2012), 494–505.
29. Chiurazzi, P., Pomponi, M.G., Willemsen, R., Oostra, B.A., Neri, G., In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum. Mol. Genet. 7 (1998), 109–113.
30. Chou, Y.W., Chaturvedi, N.K., Ouyang, S., Lin, F.F., Kaushik, D., Wang, J., Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Lett. 311:2 (2011), 177–186.
31. Chuang, D.M., Leng, Y., Marinova, Z., Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32:11 (2009), 591–601.
32. Chwang, W.B., O'Riordan, K.J., Levenson, J.M., Sweatt, J.D., ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning. Learn. Mem. 13:13 (2006), 322–328.
33. Chwang, W.B., Arthur, J.S., Schumacher, A., Sweatt, J.D., The nuclear kinase mitogen- and stress-activated protein kinase 1 regulates hippocampal chromatin remodeling in memory formation. J. Neurosci. 27:46 (2007), 12732–12742.
34. Cibelli, J.B., Campbell, K.H., Seidel, G.E., West, M.D., Lanza, R.P., The health profile of cloned animals. Nat. Biotechnol. 20 (2002), 13–14.
35. Coffee, B., Zhang, F., Ceman, S., Warren, S.T., Reines, D., Histone modifications depict an aberrantly heterochromatinized FMR1 gene in fragile X syndrome. Am. J. Hum. Genet. 71 (2002), 923–932.
36. Colon-Diaz, M., Baez-Vega, P., Garcia, M., Ruiz, A., Monteiro, J.B., Fourquet, J., Bayona, M., Alvarez-Garriga, C., Achille, A., Seto, E., Flores, I., HDAC1 and HDAC2 are differentially expressed in endometriosis. Reprod. Sci. 19:5 (2012), 483–492.
37. Colussi, C., Illi, B., Rosati, J., Spallotta, F., Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. J. Ital. Pharmacol. Soc. 62:1 (2010), 3–10.
38. Cong, P., Zhu, K., Ji, Q., Zhao, H., Chen, Y., Effects of trichostatin A on histone acetylation and methylation characteristics in early porcine embryos after somatic cell nuclear transfer. J. Anim. Sci. 84 (2013), 639–649.
39. Costa-Borges, N., Santalo, J., Ibanez, E., Comparison between the effects of valproic acid and trichostatin A on the in vitro development, blastocyst quality, and full-term development of mouse somatic cell nuclear transfer embryos. Cell. Reprogram. 12 (2010), 437–446.
40. Covington, H.E., Maze, I., LaPlant, Q.C., Vialou, V.F., Ohnishi, Y.N., Berton, O., Fass, D.M., Renthal, W., Rush, A.J., Wu, E.Y., Ghose, S., Krishnan, V., Russo, S.J., Tamminga, C., Haggarty, S.J., Nestler, E.J., Antidepressant actions of histone deacetylase inhibitors. J. Neurosci. 29 (2009), 11451–11460.
41. Covington, H.E., Vialou, V.F., LaPlant, Q., Ohnishi, Y.N., Nestler, E.J., Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci. Lett. 493 (2011), 122–126.
42. Crump, M., Coiffier, B., Jacobsen, E.D., Sun, L., Ricker, J.L., Xie, H., Frankel, S.R., Randolph, S.S., Cheson, B.D., Phase II trial of oral Vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann. Oncol. 19 (2008), 964–969.
43. Cuadrado-Tejedor, M., Ricobaraza, A.L., Torrijo, R., Franco, R., Garcia-Osta, A., Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the alzheimer's disease-like phenotype of a commonly used mouse model. Curr. Pharm. Des. 19:28 (2013), 5076–5084.
44. Dawson, T.M., Dawson, V.L., Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111 (2003), 145–151.
45. Dean, W., Santos, F., Stojkovic, M., Zakhartchenko, V., Walter, J., Wolf, E., Reik, W., Conservation of methylation reprogramming in mammalian development: aberrant reprogramming in cloned embryos. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 13734–13738.
46. Ding, X., Wang, Y., Zhang, D., Guo, Z., Zhang, Y., Increased pre-implantation development of cloned bovine embryos treated with 5-aza-2′-deoxycytidine and trichostatin A. Theriogenology 70 (2008), 622–630.
47. Dompierre, J.P., Godin, J.D., Charrin, B.C., Cordelieres, F.P., King, S.J., Humbert, S., Saudou, F., Histone deacetylase 6 inhibition compensates for the transport deficit in huntington's disease by increasing tubulin acetylation. J. Neurosci. 27 (2007), 3571–3583.
48. Duman, R.S., Heninger, G.R., Nestler, E.J., A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54 (1997), 697–706.
49. Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J.H., Reilly, J.F., Ricker, J.L., Richon, V.M., Frankel, S.R., Phase 2 trial of oral Vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109 (2007), 31–39.
50. Esteller, M., CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21 (2002), 5427–5440.
51. Evans, M.C., Cherry, J.J., Androphy, E.J., Differential regulation of the SMN2 gene by individual HDAC proteins. Biochem. Biophys. Res. Commun. 414 (2011), 25–30.
52. Faraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70 (2006), 1876–1884.
53. Farquhar, C.M., Extracts from the ‘clinical evidence’. Endometriosis. BMJ 320:7247 (2000), 1449–1452.
54. Fass, D.M., Butler, J.E., Goodman, R.H., Deacetylase activity is required for cAMP activation of a subset of CREB target genes. J. Biol. Chem. 278 (2003), 43014–43019.
55. Feng, R., Oton, A., Mapara, M.Y., Anderson, G., Belani, C., Lentzsch, S., The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br. J. Haematol. 139 (2007), 385–397.
56. Ferland, C.L., Schrader, L.A., Regulation of histone acetylation in the hippocampus of chronically stressed rats: a potential role of sirtuins. Neuroscience 174 (2011), 104–114.
57. Ferrante, R.J., Kubilus, J.K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in huntington's disease mice. J. Neurosci. 23:28 (2003), 9418–9427.
58. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., Tsai, L.H., Recovery of learning and memory is associated with chromatin remodelling. Nature 447 (2007), 178–182.
59. Fischer, A., Sananbenesi, F., Mungenast, A., Tsai, L.H., Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31:31 (2010), 605–617.
60. Fontan-Lozano, A., Romero-Granados, R., Troncoso, J., Munera, A., Delgado-Garcia, J.M., Carrion, A.M., Histone deacetylase inhibitors improve learning consolidation in young and in ka-induced-neurodegeneration and samp-8-mutant mice. Mol. Cell. Neurosci. 39:2 (2008), 193–201.
61. Foss, F., Advani, R., Duvic, M., Hymes, K.B., Intragumtornchai, T., Lekhakula, A., A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous t-cell lymphoma. Br. J. Haematol. 168:6 (2015), 811–819.
62. Fuchikami, M., Morinobu, S., Kurata, A., Yamamoto, S., Yamawaki, S., Single immobilization stress differentially alters the expression profile of transcripts of the brain-derived neurotrophic factor (BDNF) gene and histone acetylation at its promoters in the rat hippocampus. Int. J. Neuropsychopharmacol. 12 (2009), 73–82.
63. Fuchikami, M., Yamamoto, S., Morinobu, S., Okada, S., Yamawaki, Y., Yamawaki, S., The potential use of histone deacetylase inhibitors in the treatment of depression. Engl. Hist. Rev. 64:1 (2016), 3–8.
64. Garcia-Manero, G., Kantarjian, H.M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W.G., Ravandi, F., Koller, C., Xiao, L., Faderl, S., Estrov, Z., Cortes, J., O'brien, S., Estey, E., Bueso-Ramos, C., Fiorentino, J., Jabbour, E., Issa, J.P., Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108:10 (2006), 3271–3279.
65. Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W.G., Faderl, S., Koller, C., Morris, G., Rosner, G., Loboda, A., Fantin, V.R., Randolph, S.S.H., Wick, J.S., Reilly, J.F., Chen, C., Ricker, J.L., Secrist, J.P., Richon, V.M., Frankel, S.R., Kantarjian, H.M., Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [saha]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111:3 (2008), 1060–1066.
66. Gardian, G., Yang, L., Cleren, C., Calingasan, N.Y., Klivenyi, P., Beal, M.F., Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. NeuroMolecular Med. 5:3 (2004), 235–241.
67. Gardian, G., Browne, S.E., Choi, D.K., Klivenyi, P., Gregorio, J., Kubilus, J.K., Neuroprotective effects of phenylbutyrate in the n171-82q transgenic mouse model of huntington's disease. J. Biol. Chem. 280 (2005), 556–563.
68. Gasser, T., Genetics of Parkinson's disease. J. Neurol. 248 (2001), 833–840.
69. Gavin, D.P., Kartan, S., Chase, K., Grayson, D.R., Sharma, R.P., Reduced baseline acetylated histone 3 levels, and a blunted response to hdac inhibition in lymphocytes cultures from schizophrenia subjects. Schizophr. Res. 103 (2008), 330–332.
70. Gimsing, P., Hansen, M., Knudsen, L.M., Knoblauch, P., Christensen, I.J., Ooi, C.E., Buhl-Jensen, P., A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 8 (2008), 170–176.
71. Giudice, L.C., Kao, L.C., Endometriosis. Lancet 364:9447 (2004), 1789–1799.
72. Glaser, K.B., HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 74:5 (2007), 659–671.
73. Godler, D.E., Tassone, F., Loesch, D.Z., Taylor, A.K., Gehling, F., Hagerman, R.J., Burgess, T., Ganesamoorthy, D., Hennerich, D., Gordon, L., Evans, A., Choo, K.H., Slater, H.R., Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum. Mol. Genet. 19:8 (2010), 1618–1632.
74. Gojo, I., Jiemjit, A., Trepel, J.B., Sparreboom, A., Figg, W.D., Rollins, S., Tidwell, M.L., Greer, J., Chung, E.J., Lee, M.J., Phase I and pharmacologic study of ms-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109:7 (2007), 2781–2790.
75. Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O., Licht, T., Weidenfeld, J., Ben-Hur, T., Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol. Psychiatry 13 (2008), 717–728.
76. Govindarajan, N., Agis-Balboa, R.C., Walter, J., Sananbenesi, F., Fischer, A., Sodium butyrate improves memory function in an alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. 26:1 (2011), 187–197.
77. Goyal, J., Rodriguez, R., Evidence from clinical trials for the use of valproic acid in solid tumors: focus on prostate cancer. Clin. Investig. 3:5 (2013), 467–478.
78. Granger, A., Abdullah, I., Huebner, F., Stout, A., Wang, T., Huebner, T., Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 22 (2008), 3549–3560.
79. Green, K., Steffan, J.S., Martinez-Coria, H., Sun, X., Schreiber, S., Thompson, L., Laferla, F., Nicotinamide restores cognition in alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of THR231-phosphotau. J. Neurosci. 28 (2008), 11500–11510.
80. Greene, J., Banasr, M., Lee, B., Warner-Schmidt, J., Duman, R.S., Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 34 (2009), 2459–2468.
81. Guan, Z., Giustetto, M., Lomvardas, S., Kim, J.H., Miniaci, M.C., Schwartz, J.H., Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 111:4 (2002), 483–493.
82. Guan, J.S., Haggarty, S.J., Giacometti, E., Dannenberg, J.H., Joseph, N., Gao, J., HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459:7243 (2009), 55–60.
83. Gundersen, B.B., Blendy, J.A., Effects of the histone deacetylase inhibitor sodium butyrate in models of depression and anxiety. Neuropharmacology 57:1 (2009), 67–74.
84. Hahnen, E., Brichta, L., Haastert, K., Riessland, M., Claus, P., Buslei, R., In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 98:1 (2006), 193–202.
85. Hallam, T.M., Bourtchouladze, R., Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction. Cell. Mol. Life Sci. 63 (2006), 1725–1735.
86. Han, A., Sung, Y.B., Chung, S.Y., Kwon, M.S., Possible additional antidepressant-like mechanism of sodium butyrate: targeting the hippocampus. Neuropharmacology 81 (2014), 292–302.
87. Hardy, J., A hundred years of Alzheimer's disease research. Neuron 52 (2006), 3–13.
88. Hardy, J., Higgins, G.A., Alzheimer's disease: the amyloid cascade hypothesis. Science 256:5054 (1992), 184–185.
89. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:5580 (2002), 353–356.
90. Hauke, J., Riessland, M., Lunke, S., Eyupoglu, I.Y., Blumcke, I., El-Osta, A., Survival motor neuron gene 2 silencing by dna methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum. Mol. Genet. 18:2 (2009), 304–317.
91. Hay, D.G., Sathasivam, K.S., Stahl, B., Marber, M., Mestril, R., Mahal, A., Smith, D.L., Woodman, B., Bates, G.P., Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13 (2004), 1389–1405.
92. Heinrichs, S.C., Leite-Morris, K.A., Rasmusson, A.M., Kaplan, G.B., Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. Neurosci. Lett. 552:1 (2013), 108–113.
93. Hildmann, C., Riester, D., Schwienhorst, A., Histone deacetylases - an important class of cellular regulators with a variety of functions. Appl. Microbiol. Biotechnol. 75 (2007), 487–497.
94. Hisaoka, K., Nishida, A., Koda, T., Miyata, M., Zensho, H., Morinobu, S., Antidepressant drug treatments induce glial cell line-derived neurotrophic factors (GDNF) synthesis and release in rat C6 glioblastoma cells. J. Neurochem. 79 (2001), 25–34.
95. Hockly, E., Richon, V.M., Woodman, B., Smith, D.L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P.A., Steffan, J.S., Marsh, J.L., Thompson, L.M., Lewis, C.M., Marks, P.A., Bates, G.P., Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of huntington's disease. Proc. Natl. Acad. Sci. 100:4 (2003), 2041–2046.
96. Hollis, F., Wang, H., Dietz, D., Gunjan, A., Kabbaj, M., The effects of repeated social defeat on longterm depressive-like behavior and short-term histone modifications in the hippocampus in male Sprague-Dawley rats. Psychopharmacology 211 (2010), 69–77.
97. Hou, L., Ma, F., Yang, J., Riaz, H., Wang, Y., Wu, W., Xia, X., Ma, Z., Zhou, Y., Zhang, L., Ying, W., Xu, D., Zuo, B., Ren, Z., Xiong, Y., Effects of histone deacetylase inhibitor oxamflatin on in vitro porcine somatic cell nuclear transfer embryos. Cell. Reprogram. 16 (2014), 253–265.
98. Hu, E., Dul, E., Sung, C.M., Chen, Z., Kirkpatrick, R., Zhang, G.F., Johanson, K., Liu, R., Lago, A., Hofmann, G., Macarron, R., de los Frailes, M., Perez, P., Krawiec, J., Winkler, J., Jaye, M., Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307 (2003), 720–728.
99. Hu, S., Ni, W., Chen, C., Sai, W., Hazi, W., He, Z., Comparison between the effects of valproic acid and trichostatin A on in vitro development of sheep somatic cell nuclear transfer embryos. J. Anim. Vet. Adv. 11 (2012), 1868–1872.
100. Huang, J., Chen, Y.J., Bian, W.H., Yu, J., Zhao, Y.W., Liu, X.Y., Unilateral amyloid-β25-35 injection into the rat amygdala increases the expressions of aberrant τ phosphoryltion kinases. Chin. Med. J. 123:10 (2010), 1311–1314.
101. Iizuka, M., Smith, M.M., Functional consequences of histone modifications. Curr. Opin. Genet. Dev. 13 (2003), 154–160.
102. Imesch, P., Fink, D., Fedier, A., Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertil. Steril. 94:7 (2010), 2838–2842.
103. Imesch, P., Samartzis, E.P., Schneider, M., Fink, D., Fedier, A., Inhibition of transcription, expression, and secretion of the vascular epithelial growth factor in human epithelial endometriotic cells by romidepsin. Fertil. Steril. 95:5 (2011), 1579–1583.
104. Inoue, K., Kohda, T., Lee, J., Ogonuki, N., Mochida, K., Noguchi, Y., Tanemura, K., Kaneko-Ishino, T., Ishino, F., Ogura, A., Faithful expression of imprinted genes in cloned mice. Science, 295(5553), 2002, 297.
105. Izawa, M., Taniguchi, F., Uegaki, T., Takai, E., Iwabe, T., Terakawa, N., Harada, T., Demethylation of a nonpromoter cytosine-phosphate-guanine island in the aromatase gene may cause the aberrant up-regulation in endometriotic tissues. Fertil. Steril. 95:1 (2011), 33–39.
106. Jasek, E., Lis, G.J., Jasinska, M., Jurkowska, H., Litwin, J.A., Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells. Anticancer Res. 32:7 (2012), 2791–2799.
107. Jichan, N., Xishi, L., Guo, S.W., Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent. Reprod. Sci. 17:11 (2010), 995–1005.
108. Jin, J.X., Kang, J.D., Li, S., Jin, L., Zhu, H.Y., Guo, Q., Gao, Q.S., Yan, C.G., Yin, X.J., Pxd101 significantly improves nuclear reprogramming and the in vitro developmental competence of porcine scnt embryos. Biochem. Biophys. Res. Commun. 456 (2015), 156–161.
109. Johnson, J.D., Campisi, J., Sharkey, C.M., Kennedy, S.L., Nickerson, M., Greenwood, B.N., Fleshner, M., Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neurosci. 135:4 (2005), 1295–1307.
110. Johnstone, R.W., Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002), 287–299.
111. Kang, Y.K., Koo, D.B., Park, J.S., Choi, Y.H., Chung, A.S., Lee, K.K., Han, Y.M., Aberrant methylation of donor genome in cloned bovine embryos. Nat. Genet. 28 (2001), 173–177.
112. Kang, J., Chen, J., Zhang, D., Da, W., Ou, Y., Synergistic killing of human leukemia cells by antioxidants and trichostatin A. Cancer Chemother. Pharmacol. 54:6 (2005), 537–545.
113. Kassis, H., Shehadah, A., Li, C., Zhang, Y., Cui, Y., Roberts, C., Sadry, N., Liu, X., Chopp, M., Zhang, Z.G., Class iia histone deacetylases affect neuronal remodeling and functional outcome after stroke. Neurochem. Int. 96 (2016), 24–31.
114. Kawagoe, R., Kawagoe, H., Sano, K., Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk. Res. 26:5 (2002), 495–502.
115. Kawano, Y., Nasu, K., Li, H., Tsuno, A., Abe, W., Takai, N., Narahara, H., Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target. Hum. Reprod. 26:9 (2011), 2486–2498.
116. Kazantsev, A.G., Thompson, L.M., Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 7:10 (2008), 854–868.
117. Kelly, W.K., Richon, V.M., O'Connor, O., Curley, T., Macgregorcurtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., Rosa, E., Drobnjak, M., Cordon-Cordo, C., Chiao, J.H., Rifkind, R., Marks, P.A., Scher, H., Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9:10 (2003), 3578–3588.
118. Kelly, D.L., Conley, R.R., Feldman, S., Yang, Y., Mcmahon, R.P., Richardson, C.M., Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatry Q. 77 (2006), 81–95.
119. Kernochan, L.E., Russo, M.L., Woodling, N.S., Huynh, T.N., Avila, A.M., Fischbeck, K.H., Sumner, C.J., The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 14 (2005), 1171–1182.
120. Khan, O., La Thangue, N.B., HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol., 90, 2012, 85e94.
121. Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S.C., Carey, N., Finn, P.W., Collins, L.S., Tumber, A., Ritchie, J.W., Jensen, P.B., Lichenstein, H.S., Sehested, M., Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. J. Biochem. 409 (2008), 581–589.
122. Kilgore, M., Fass, M.D.M., Inhibitors of class i histone deacetylases reverse contextual memory deficits in a mouse model of alzheimer's disease. Neuropsychopharmacology 35:4 (2010), 870–878.
123. Kim, J., Park, H.J., Choi, W., Kim, H., Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells. Anticancer Res. 27:5 (2007), 3285–3292.
124. Kim, H.J., Rowe, M., Ren, M., Hong, J.S., Chen, P.S., Chuang, D.M., Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321 (2007), 892–901.
125. Kim, J.J., Taylor, H.S., Lu, Z., Ladhani, O., Hastings, J.M., Jackson, K.S., Wu, Y., Guo, S.W., Fazleabas, A.T., Altered expression of HOXA10 in endometriosis: potential role in decidualization. Mol. Hum. Reprod. 13:5 (2007), 323–332.
126. Kim, H.J., Leeds, P., Chuang, D.M., The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J. Neurochem. 110 (2009), 1226–1240.
127. Kinrys, G., Pollack, M.H., Simon, N.M., Worthington, J.J., Nardi, A.E., Versiani, M., Valproic acid for the treatment of social anxiety disorder. Int. Clin. Psychopharmacol. 18:3 (2003), 169–172.
128. Kirschbaum, M.H., Foon, K.A., Frankel, P., Ruel, C., Pulone, B., Tuscano, J.M., Newman, E.M., A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium study. Leuk. Lymphoma 55:10 (2014), 2301–2304.
129. Kishigami, S., Mizutani, E., Ohta, H., Hikichi, T., Thuan, N.V., Wakayama, S., Bui, H.T., Wakayama, T., Significant improvement of mouse cloning technique by treatment with trichostatin A after somatic nuclear transfer. Biochem. Biophys. Res. Commun. 340 (2006), 183–189.
130. Kishigami, S., Bui, H.T., Wakayama, S., Tokunaga, K., Van Thuan, N., Hikichi, T., Mizutani, E., Ohta, H., Suetsugu, R., Sata, T., Successful mouse cloning of an outbred strain by trichostatin A treatment after somatic nuclear transfer. J. Reprod. Dev. 53 (2007), 165–170.
131. Kishigami, S., Wakayama, S., Hosoi, Y., Iritani, A., Wakayama, T., Somatic cell nuclear transfer: infinite reproduction of a unique diploid genome. Exp. Cell Res. 314 (2008), 1945–1950.
132. Kontopoulos, E., Parvin, J.D., Feany, M.B., Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15:20 (2006), 3012–3023.
133. Koo, J.W., Russo, S.J., Ferguson, D., Nestler, E.J., Duman, R.S., Nuclear factorkappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 2669–2674.
134. Korzus, E., Rosenfeld, M.G., Mayford, M., CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42:6 (2004), 961–972.
135. Koshibu, K., Graff, J., Beullens, M., Heitz, F.D., Berchtold, D., Russig, H., Farinelli, M., Bollen, M., Mansuy, I.M., Protein phosphatase 1 regulates the histone code for long-term memory. J. Neurosci. 29 (2009), 13079–13089.
136. Kouraklis, G., Progress in cancer gene therapy. Acta Oncol. 38 (1999), 675–683.
137. Kouraklis, G., Theocharis, S., Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol. Rep. 15:2 (2006), 489–494.
138. Kuefer, R., Hofer, M.D., Altug, V., Zorn, C., Genze, F., Kunzi-Rapp, K., Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br. J. Cancer 90:2 (2004), 535–541.
139. Kuefer, R., Genze, F., Zugmaier, W., Rinnab, L., Hautmann, R.E., Buechele, B., Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl) retinamide on prostate cancer. Neoplasia 9:3 (2007), 246–253.
140. Kumar, A., Singh, S.K., Kumar, V., Kumar, D., Agarwal, S., Rana, M.K., Huntington's disease: an update of therapeutic strategies. Gene 556:2 (2015), 91–97.
141. Labrie, V., Histone deacetylase inhibitors: a novel therapeutic approach for cognitive disorders. Epigenet. Hum. Health, 2011, 245–266.
142. Lagneaux, L., Gillet, N., Stamatopoulos, B., Delforge, A., Dejeneffe, M., Massy, M., Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates trail response. Exp. Hematol. 35:10 (2007), 1527–1537.
143. Lal, H., Shearman, G.T., Fielding, S., Dunn, R., Kruse, H., Theurer, K., Effect of valproic acid on anxiety-related behaviors in the rat. Brain Res. Bull. 5:80 (1980), 575–577.
144. Latham, K.E., Early and delayed aspects of nuclear reprogramming during cloning, Biol. Cell 97 (2005), 119–132.
145. Laurent, R.S., O'Brien, L.M., Ahmad, S.T., Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila, model of parkinson's disease. Neuroscience 246 (2013), 382–390.
146. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., Paslier, D.L., Frezal, J., Cohen, D., Weissenbach, J., Munnich, A., Melki, J., Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:1 (1995), 155–165.
147. Leiva, M., Moretti, S., Soilihi, H., Pallavicini, I., Peres, L., Mercurio, C., Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia 26:7 (2012), 1630–1637.
148. Levenson, J.M., O'Riordan, K.J., Brown, K.D., Trinh, M.A., Molfese, D.L., Sweatt, J.D., Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279 (2004), 40545–40559.
149. Li, J., Svarcova, O., Villemoes, K., Kragh, P.M., Schmidt, M., Bogh, I.B., Zhang, Y., Du, Y., Lin, L., Purup, S., High in vitro development after somatic cell nuclear transfer and trichostatin A treatment of reconstructed porcine embryos. Theriogenology 70 (2008), 800–808.
150. Li, X., Liu, X., Guo, S.W., Histone deacetylase inhibitors as therapeutics for endometriosis. Exp. Rev. Obstet. Gynecol. 7:7 (2014), 451–466.
151. Li, L., Fan, B., Zhang, L.H., Xing, X.F., Cheng, X.J., Wang, X.H., Guo, T., Du, H., Wen, X.Z., Trichostatin a potentiates trail-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer. Tumor Biol., 2016, 1–10.
152. Lieb, J.D., Clarke, N.D., Control of transcription through intragenic patterns of nucleosome composition. Cell 123 (2005), 1187–1190.
153. Lim, K.L., Dawson, V.L., Dawson, T.M., The genetics of Parkinson's disease. Curr. Neurol. Neurosci. Rep. 2 (2002), 439–446.
154. Lin, H., Geng, X., Dang, W., Wu, B., Dai, Z., Li, Y., Yang, Y., Zhang, H., Shi, J., Molecular mechanisms associated with the antidepressant effects of the class I histone deacetylase inhibitor MS-275 in the rat ventrolateral orbital cortex. Brain Res. 1447 (2012), 119–125.
155. Liu, X., Lei, Y., Guo, S.W., Valproic acid as a therapy for adenomyosis: a comparative case series. Reprod. Sci. 17:10 (2010), 904–912.
156. Liu, M., Liu, X., Zhang, Y., Guo, S.W., Valproic acid and progestin inhibit lesion growth and reduce hyperalgesia in experimentally induced endometriosis in rats. Reprod. Sci. 19:4 (2012), 360–373.
157. Liu, X., Nie, J., Guo, S.W., Elevated immunoreactivity against Class I histone deacetylases (HDACs) in adenomyosis. Gynecol. Obstet. Investig. 74 (2012), 50–55.
158. Liu, X.S., Chopp, M., Kassis, H., Jia, L.F., Hozeska-Solgot, A., Zhang, R.L., Chen, C., Cui, Y.S., Zhang, Z.G., Valproic acid increases white matter repair and neurogenesis after stroke. Neuroscience 220:38 (2012), 313–321.
159. Liu, H., Yazdani, A., Murray, L.M., Beauvais, A., Kothary, R., The SMN-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy. PLoS One, 9(7), 2014, e101225.
160. Liu, H., Zhang, J.J., Li, X., Yang, Y., Xie, X.F., Hu, K., Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion. Pharmacol. Biochem. Behav. 135 (2015), 53–59.
161. Lorenz, V., Hessenkemper, W., Rodiger, J., Kyrylenko, S., Kraft, F., Baniahmad, A., Sodium butyrate induces cellular senescence in neuroblastoma and prostate cancer cells. Horm. Mol. Biol. Clin. Invest. 7:1 (2011), 265–272.
162. Lu, Y., Nie, J., Liu, X., Zheng, Y., Guo, S.W., Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice. Hum. Reprod. 25:4 (2010), 1014–1025.
163. Lunke, S., El-Osta, A., Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy. Neurotherapeutics 10:4 (2013), 677–687.
164. Luo, C., Lu, F., Wang, X., Wang, Z., Li, X., Gong, F., Jiang, J., Liu, Q., Shi, D., Treatment of donor cells with trichostatin A improves invitro development and reprogramming of buffalo (Bubalus bubalis) nucleus transfer embryos. Theriogenology 80 (2013), 878–886.
165. Luo, B., Ju, S., Muneri, C.W., Rui, R., Effects of histone acetylation status on the early development of in vitro porcine transgenic cloned embryos. Cell. Reprogram. 17 (2015), 41–48.
166. Luu, T.H., Morgan, R.J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D.D., Doroshow, J.H., Wong, C., Aparicio, A., Gandara, D.R., Somlo, G., A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin. Cancer Res. 14:21 (2008), 7138–7142.
167. Maggio, S.C., Rosato, R.R., Kramer, L.B., Dai, Y., Rahmani, M., Paik, D.S., Czarnik, A.C., Payne, S.G., Spiegel, S., Grant, S., The histone deacetylase inhibitor ms-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 64:7 (2004), 2590–2600.
168. Mann, B.S., Johnson, J.R., He, K., Sridhara, R., Abraham, S., Booth, B.P., Verbois, L., Morse, D.E., Jee, J.M., Pope, S., Harapanhalli, R.S., Dagher, R., Farrell, A., Justice, R., Pazdur, R., Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 13 (2007), 2318–2322.
169. Meisel, A., Harms, C., Yildirim, F., Bosel, J., Kronenberg, G., Harms, U., Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J. Neurochem. 98 (2006), 1019–1031.
170. Meng, Q., Polgar, Z., Liu, J., Dinnyes, A., Live birth of somatic cell-cloned rabbits following trichostatin A treatment and cotransfer of parthenogenetic embryos. Cloning Stem Cells 11 (2009), 203–208.
171. Minamiyama, M., Katsuno, M., Adachi, H., Waza, M., Sang, C., Kobayashi, Y., Tanaka, F., Doyu, M., Inukai, A., Sobue, G., Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13:11 (2004), 1183–1192.
172. Miyoshi, K., Mori, H., Mizobe, Y., Akasaka, E., Ozawa, A., Yoshida, M., Sato, M., Valproic acid enhancesin vitro development and Oct-3/4 expression of miniature pig somatic cell nuclear transfer embryos. Cell. Reprogram. 12 (2010), 67–74.
173. Moynihan, A.T., Hehir, M.P., Sharkey, A.M., Robson, S.C., Europe-Finner, G.N., Morrison, J.J., Histone deacetylase inhibitors and a functional potent inhibitory effect on human uterine contractility. Am. J. Obstet. Gynecol., 199(2), 2008 (167. e1-7).
174. Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J., Monteggia, L.M., Neurobiology of depression. Neuron 34 (2002), 13–25.
175. O'Connor, O.A., Heaney, M.L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24 (2006), 166–173.
176. O'Donnell, W.T., Warren, S.T., A decade of molecular studies of fragile X syndrome. Annu. Rev. Neurosci. 25 (2002), 315–338.
177. Ohgane, J., Wakayama, T., Senda, S., Yamazaki, Y., Inoue, K., Ogura, A., Marh, J., Tanaka, S., Yanagimachi, R., Shiota, K., The Sall3 locus is an epigenetic hotspot of aberrant DNA methylation associated with placentomegaly of cloned mice. Genes Cells 9 (2004), 253–260.
178. Oliveira, A.M., Wood, M.A., McDonough, C.B., Abel, T., Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits. Learn. Mem. 14 (2007), 564–572.
179. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Phase IIB multicenter trial of Vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25 (2007), 3109–3115.
180. Ono, T., Li, C., Mizutani, E., Terashita, Y., Yamagata, K., Wakayama, T., Inhibition of class IIb histone deacetylase significantly improves cloning efficiency in mice. Biol. Reprod. 83 (2010), 929–937.
181. Ota, H., Igarashi, S., Sasaki, M., Tanaka, T., Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum. Reprod. 16:3 (2001), 561–566.
182. Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., Amore, A.M., Volk, C.B., Maxwell, M.M., Rochet, J.C., McLean, P.J., Young, A.B., Abagyan, R., Feany, M.B., Hyman, B.T., Kazantsev, A.G., Sirtuin 2 inhibitors rescue alpha-synucleinmediated toxicity in models of Parkinson's disease. Science 317 (2007), 516–519.
183. Pallos, J., Bodai, L., Lukacsovich, T., Purcell, J.M., Steffan, J.S., Thompson, L.M., Inhibition of specific hdacs and sirtuins suppresses pathogenesis in a drosophila model of huntington's disease. Hum. Mol. Genet. 17 (2008), 3767–3775.
184. Pan, L., Matloob, A.F., Du, J., Pan, H., Dong, Z., Zhao, J., Vitamind stimulates apoptosis in gastric cancer cells in synergy with trichostatina /sodium butyrate-induced and 5-aza-2′-deoxycytidine-induced pten upregulation. Febs J. 277:4 (2010), 989–999.
185. Peiffer, L., Poll-Wolbeck, S.J., Flamme, H., Gehrke, I., Hallek, M., Kreuzer, K.A., Trichostatin a effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of WNT signaling and histone deacetylation. J. Cancer Res. Clin. Oncol. 140:8 (2014), 1283–1293.
186. Peleg, S., Fischer, A., Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328 (2010), 753–756.
187. Pelliccioni, M., D'Amico, A., Colitto, F., Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord. 14:2 (2004), 130–135.
188. Petrif, F., Giles, R., Dauwerse, H., Saris, J., Hennekam, R.C.M., Masuno, M., Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376:6538 (1995), 348–351.
189. Phiel, C.J., Zhang, F., Huang, E.Y., Guenther, M.G., Lazar, M.A., Klein, P.S., Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276 (2001), 36734–36741.
190. Philippe, J., Drucker, D.J., Chick, W.L., Habener, J.F., Transcriptional regulation of genes encoding insulin, glucagon, and angiotensinogen by sodium butyrate in a rat islet cell line. Mol. Cell. Biol. 7:1 (1987), 560–563.
191. Pieretti, M., Zhang, F., Fu, Y.H., Warren, S.T., Oostra, B.A., Caskey, C.T., Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66:4 (1991), 817–822.
192. Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J., La Thangue, N.B., Brown, R., Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor pxd101. Mol. Cancer Therapeut. 2:8 (2003), 721–728.
193. Qi, X., Hosoi, T., Okuma, Y., Kaneko, M., Nomura, Y., Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66 (2004), 899–908.
194. Qing, H., He, G., Ly, P.T., Fox, C.J., Staufenbiel, M., Cai, F., Valproic acid inhibits abeta production, neuritic plaque formation, and behavioral deficits in alzheimer's disease mouse models. J. Exp. Med. 205 (2008), 2781–2789.
195. Qiu, J., Yamamoto, S., Maruyama, T., Kondoh, N., Nojima, M., Shima, H., Growth suppression of prostate cancer cells by sodium butyrate in vitro. Acta Medica Hyogoensia 32 (2007), 77–85.
196. Qiu, J., Gao, Z., Shima, H., Growth of human prostate cancer cells is significantly suppressed in, vitro with sodium butyrate through apoptosis. Oncol. Rep. 27:1 (2011), 160–167.
197. Qiu, X.Y., You, H., Xiao, X., Li, N., Li, Y.M., Effects of trichostatin A and PXD101 on the in vitro development of mouse somatic cell nuclear transfer embryos. Biochem. Biophy. Res. Commun., 2016 (Under Review).
198. Ren, M., Leng, Y., Jeong, M., Leeds, P.R., Chuang, D.M., Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89 (2004), 1358–1367.
199. Renthal, W., Maze, I., Krishnan, V., Covington, H.E., Xiao, G., Kumar, A., Russo, S.J., Graham, A., Tsankova, N., Kippin, T.E., Kerstetter, K.A., Neve, R.L., Haggarty, S.J., McKinsey, T.A., Bassel-Duby, R., Olson, E.N., Nestler, E.J., Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 56 (2007), 517–529.
200. Ricobaraza, A., Cuadrado-Tejedor, M., Perez-Mediavilla, A., Frechilla, D., Del Rio, J., Garcia-Osta, A., Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an alzheimer's disease mouse model. Neuropsychopharmacology 34:7 (2009), 1721–1732.
201. Ricobaraza, A., Cuadrado-Tejedor, M., Marco, S., Perez-Otano, I., Garcia-Osta, A., Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of alzheimer disease. Hippocampus 22:5 (2012), 1040–1050.
202. Riessland, M., Brichta, L., Hahnen, E., Wirth, B., The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 120:1 (2006), 101–110.
203. Roelfsema, J.H., White, S.J., Ariyürek, Y., Bartholdi, D., Niedrist, D., Papadia, F., Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP, and EP300, genes cause disease. Am. J. Hum. Genet. 76 (2005), 572–580.
204. Ropero, S., Esteller, M., The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 1:1 (2007), 19–25.
205. Rybouchkin, A., Kato, Y., Tsunoda, Y., Role of histone acetylation inreprogramming of somatic nuclei following nuclear transfer. Biol. Reprod. 74 (2006), 1083–1089.
206. Sadri-Vakili, G., Bouzou, B., Benn, C.L., Kim, M.O., Chawla, P., Overland, R.P., Histones associated with downregulated genes are hypo-acetylated in huntington's disease models. Hum. Mol. Genet. 16 (2007), 1293–1306.
207. Santos, F., Zakhartchenko, V., Stojkovic, M., Peters, A., Jenuwein, T., Wolf, E., Reik, W., Dean, W., Epigenetic marking correlates with developmental potential in cloned bovine preimplantation embryos. Curr. Biol. 13 (2003), 1116–1121.
208. Santos, M.P.D., Schwartsmann, G., Roesler, R., Brunetto, A.L., Abujamra, A.L., Sodium butyrate enhances the cytotoxic effect of antineoplastic drugs in human lymphoblastic T-cells. Leuk. Res. 33:2 (2009), 218–221.
209. Saunders, N., Dicker, A., Popa, C., Jones, S., Dahler, A., Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 59 (1999), 399–404.
210. Schroeder, F.A., Lin, C.L., Crusio, W.E., Akbarian, S., Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in themouse. Biol. Psychiatry 62 (2007), 55–64.
211. Shabbeer, S., Madeleine, S.Q.K., Kachhap, S., Galloway, N., Rodriguez, R., Carducci, M.A., Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate 67:10 (2007), 1099–1110.
212. Sharma, S., Taliyan, R., Ramagiri, S., Histone deacetylase inhibitor, trichostatin a, improves learning and memory in high-fat diet-induced cognitive deficits in mice. J. Mol. Neurosci. 56:1 (2014), 1–11.
213. Sharma, S., Taliyan, R., Singh, S., Beneficial effects of sodium butyrate in 6-ohda induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav. Brain Res. 291 (2015), 306–314.
214. Shi, L.H., Miao, Y.L., Ouyang, Y.C., Huang, J.C., Lei, Z.L., Yang, J.W., Trichostatin A (TSA) improves the development of rabbit-rabbit intraspecies cloned embryos, but not rabbit-human interspecies cloned embryos. Dev. Dyn. 237 (2008), 640–648.
215. Simonini, M.V., Camargo, L.M., Dong, E., Maloku, E., Veldic, M., Costa, E., The benzamide ms-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc. Natl. Acad. Sci. 103:5 (2006), 1587–1592.
216. Sinn, D.I., Kim, S., Chu, K., Jung, K.H., Lee, S.T., Song, E.C., Kim, J.M., Park, D.K., Lee, S.K., Kim, M., Roha, J.K., Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol. Dis. 26 (2007), 464–472.
217. Sjoholm, A., Sodium butyrate inhibits rat insulinoma cell proliferation without affecting the cellular insulin content or insulin release. Anti-Cancer Drugs 4:2 (1993), 259–263.
218. Solter, D., Mammalian cloning: advances and limitations. Nat. Rev. Genet. 1 (2000), 199–207.
219. Steffan, J.S., Bodai, L., Pallos, J., Poelman, M., Mccampbell, A., Apostol, B.L., Kazantsev, A., Schmidt, E., Zhu, Y., Greenwald, M., Kurokawa, R., Housman, D.E., Jackson, G.R., Marsh, J.L., Thompson, L.M., Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:6857 (2001), 739–743.
220. Strobl, J.S., Nikkhah, M., Agah, M., Actions of the anti-cancer drug suberoylanilide hydroxamic acid (SAHA) on human breast cancer cytoarchitecture in silicon microstructures. Biomaterials 31:27 (2010), 7043–7050.
221. Su, Y., Ryder, J., Li, B., Wu, X., Fox, N., Solenberg, P., Lithium, a common drug for bipolar disorder treatment, regulates amyloid-β precursor protein processing. Biochemistry 43 (2004), 6899–6908.
222. Su, J., Wang, Y., Li, Y., Li, R., Li, Q., Wu, Y., Quan, F., Liu, J., Guo, Z., Zhang, Y., Oxamflatin significantly improves nuclear reprogramming, blastocyst quality, and in vitro development of bovine scnt embryos. PLoS One 6 (2011), 449–453.
223. Sugars, K.L., Rubinsztein, D.C., Transcriptional abnormalities in Huntington disease. Trends Genet. 19 (2003), 233–238.
224. Sumner, C.J., Huynh, T.N., Markowitz, J.A., Perhac, J.S., Hill, B., Coovert, D.D., Schussler, K., Chen, X., Jarecki, J., Burghes, A.H.M., Taylor, J.P., Fischbeck, K.H., Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 54 (2003), 647–654.
225. Sun, X., Wei, L., Chen, Q., Terek, R.M., HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating runx2 activity. J. Biol. Chem. 284 (2009), 21881–21890.
226. Suo, H., Pan, W., Tong, J., Lei, C., Jie, L., Huang, D., NRSF is an essential mediator for the neuroprotection of trichostatin A in the MPTP mouse model of parkinson's disease. Neuropharmacology 99 (2015), 67–78.
227. Suzuki, T., Uchida, H., Takeuchi, H., Nakajima, S., Nomura, K., Tanabe, A., Yagi, G., Watanabe, K., Kashima, H., Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum. Psychopharmacol. 24 (2009), 628–638.
228. Swarovsky, B., Eissele, R., Eisenacher, M., Trautmann, M.E., Arnold, R., Sodium butyrate induces neuroendorine cytodifferentiation in the insulinoma cell line RINM5F. Pancreas 9:4 (1994), 460–468.
229. Szczepanska, M., Wirstlein, P., Luczak, M., Jagodzinski, P.P., Skrzypczak, J., Reduced expression of HOXA10 in the midluteal endometrium from infertile women with minimal endometriosis. Biomed. Pharmacother. 64:10 (2010), 697–705.
230. Tabolacci, E., De, P.I., Accadia, M., Terracciano, A., Moscato, U., Chiurazzi, P., Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet. Genomics 18:8 (2008), 738–741.
231. Tagawa, K., Marubuchi, S., Qi, M.L., Enokido, Y., Tamura, T., Inagaki, R., Murata, M., Kanazawa, I., Wanker, E.E., Okazawa, H., The induction levels of heat shock protein 70 differentiate the vulnerabilities to mutant huntingtin among neuronal subtypes. J. Neurosci. 27 (2007), 868–880.
232. Thelen, P., Schweyer, S., Hemmerlein, B., Wuttke, W., Seseke, F., Ringert, R.H., Expressional changes after histone deacetylase inhibition by valproic acid in lncap human prostate cancer cells. Int. J. Oncol. 24:1 (2004), 25–31.
233. Thomas, E.A., Coppola, G., Desplats, P.A., Tang, B., Soragni, E., Burnett, R., The hdac inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in huntington's disease transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 105:40 (2008), 15564–15569.
234. Timmerman, S., Lehrmann, H., Popesskaya, A., Harel-Bellan, A., Histone acetylation and disease. Cell. Mol. Life Sci. 58 (2001), 728–736.
235. Tsai, L.K., Yang, C.C., Hwu, W.L., Li, H., Valproic acid treatment in six patients with spinal muscular atrophy. Eur. J. Neurol. 14 (2007), e8–e9.
236. Tsankova, N.M., Berton, O., Renthal, W., Kumar, A., Neve, R.L., Nestler, E.J., Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9 (2006), 519–525.
237. Tsubaki, J., Hwa, V., Twigg, S.M., Rosenfeld, R.G., Differential activation of the igf binding protein3 promoter by butyrate in prostate cancer cells. Endocrinology 143:5 (2002), 1778–1788.
238. Uchida, H., Maruyama, T., Ohta, K., Ono, M., Arase, T., Kagami, M., Oda, H., Kajitani, T., Asada, H., Yoshimura, Y., Histone deacetylase inhibitor-induced glycodelin enhances the initial step of implantation. Hum. Reprod. 22:10 (2007), 2615–2622.
239. Uchida, S., Hara, K., Kobayashi, A., Otsuki, K., Yamagata, H., Hobara, T., Epigenetic status of gdnf, in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 69:2 (2011), 359–372.
240. Vadnal, J., Houston, S., Bhatta, S., Freeman, E., Mcdonough, J., Transcriptional signatures mediated by acetylation overlap with early-stage alzheimer's disease. Exp. Brain Res. 221:3 (2012), 287–297.
241. Van Thuan, N., Bui, H.T., Kim, J.H., Hikichi, T., Wakayama, S., Kishigami, S., Mizutani, E., Wakayama, T., The histone deacetylase inhibitor scriptaid enhances nascent mRNA production and rescues full-term development in cloned inbred mice. Reproduction 138 (2009), 309–317.
242. Vecsey, C.G., Hawk, J.D., Lattal, K.M., Stein, J.M., Fabian, S.A., Attner, M.A., Cabrera, S.M., McDonough, C.B., Brindle, P.K., Abel, T., Wood, M.A., Histone deacetylase inhibitors enhance memory and synaptic plasticity via creb: cbp-dependent transcriptional activation. J. Neurosci. 27:23 (2007), 6128–6140.
243. Verdin, E., Ott, M., 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat. Rev. Mol. Cell Biol. 16:4 (2015), 258–264.
244. Verkerk, A.J.M.H., Pieretti, M., Sutcliffe, J.S., Fu, Y.H., Kuhl, D.P.A., Pizzuti, A., Identification of a gene (fmr-1) containing a cgg repeat coincident with a breakpoint cluster region exhibiting length variation in fragile x syndrome. Cell 65:5 (1991), 905–914.
245. Vmd, H.L.N., Kong, L., Burnett, B.G., Ba, D.W.C., Bosch-Marce, M., Taye, A.A., Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition. Ann. Neurol. 64:4 (2008), 465–470.
246. Wang, F., Kou, Z., Zhang, Y., Gao, S., Dynamic reprogramming of histone acetylation and methylation in the first cell cycle of cloned mouse embryos. Biol. Reprod. 77 (2007), 1007–1016.
247. Warrell, R.P., He, L., Richon, V., Calleja, E., Pandolfi, P., Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90 (1998), 1621–1625.
248. Wassef, A.A., Dott, S.G., Harris, A., Brown, A., O'Boyle, M., Rose, R.M., Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J. Clin. Psychopharmacol. 20 (2000), 357–361.
249. Weaver, I.C., Cervoni, N., Champagne, F.A., D'Alessio, A.C., Sharma, S., Seckl, J.R., Dymov, S., Szyf, M., Meaney, M.J., Epigenetic programming by maternal behavior. Nat. Neurosci. 7 (2004), 847–854.
250. Weaver, I.C., Meaney, M.J., Szyf, M., Maternal care effects on the hippocampal transcriptome and anxiety-mediated behaviors in the offspring that are reversible in adulthood. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 3480–3485.
251. Wedel, S., Hudak, L., Seibel, J.M., Juengel, E., Tsaur, I., Wiesner, C., Haferkamp, A., Blaheta, R.A., Inhibitory effects of the hdac inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mtor inhibitor rad001. Life Sci. 88:9 (2011), 418–424.
252. Wee, G., Koo, D.B., Song, B.S., Kim, J.S., Kang, M.J., Moon, S.J., Kang, Y.K., Lee, K.K., Han, Y.M., Inheritable histone H4 acetylation of somatic chromatins in cloned embryos. J. Biol. Chem. 281 (2006), 6048–6057.
253. Weeber, E.J., Levenson, J.M., Sweatt, J.D., Molecular genetics of human cognition. Mol. Interv. 2 (2002), 376–391.
254. Weihl, C.C., Connolly, A.M., Pestronk, A., Valproate may improve strength and function in patients with type iii/iv spinal muscle atrophy. Neurology 67:3 (2006), 500–501.
255. Weiler, I.J., Greenough, W.T., Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 5395–5400.
256. Wen, B.Q., Li, J., Li, J.J., Tian, S.J., Sun, S.C., Qi, X., Cai, W.T., Chang, Q.L., The histone deacetylase inhibitor scriptaid improves in vitro developmental competence of ovine somatic cell nuclear transferred embryos. Theriogenology 8 (2014), 332–339.
257. Whittle, N., Schmuckermair, C., Cinar, O.G., Hauschild, M., Ferraguti, F., Holmes, A., Singewald, N., Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model. Neuropharmacology 64:4 (2013), 414–423.
258. Wilmut, I., Paterson, L., Somatic cell nuclear transfer. Nature 419 (2002), 303–307.
259. Wood, M.A., Kaplan, M.P., Park, A., Blanchard, E.J., Oliveira, A.M., Lombardi, T.L., Abel, T., Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn. Mem. 12:2 (2005), 111–119.
260. Wu, Y., Strawn, E., Basir, Z., Halverson, G., Guo, S.W., Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. Epigenetics 1:2 (2006), 106–111.
261. Wu, Y., Starzinski-Powitz, A., Guo, S.W., Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod. Sci. 14:4 (2007), 374–382.
262. Wu, X., Chen, P.S., Dallas, S., Wilson, B., Block, M.L., Wang, C.C., Kinyamu, H., Lu, N., Gao, X., Leng, Y., Chuang, D.M., Zhang, W., Lu, R.B., Hong, J.S., Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int. J. Neuropsychopharmacol. 11 (2008), 1123–1134.
263. Wu, Y., Starzinski-Powitz, A., Guo, S.W., Constitutive and tumor necrosis factoralpha- stimulated activation of nuclear factor-kappaB in immortalized endometriotic cells and their suppression by trichostatin A. Gynecol. Obstet. Investig. 70:1 (2010), 23–33.
264. Xu, K., Dai, X.L., Huang, H.C., Jiang, Z.F., Targeting hdacs: a promising therapy for alzheimer's disease. Oxidative Med. Cell. Longev., 2011(1942-0900), 2011, 143269.
265. Xu, W., Wang, Y., Li, Y., Wang, L., Xiong, X., Su, J., Zhang, Y., Valproic acid improves the in vitro development competence of bovine somatic cell nuclear transfer embryos. Cell. Reprogram. 14 (2012), 138–145.
266. Yamawaki, Y., Fuchikami, M., Morinobu, S., Segawa, M., Matsumoto, T., Yamawaki, S., Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J. Biol. Psychiatry 13 (2012), 458–467.
267. Yang, X.J., Seto, E., The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9:3 (2008), 206–218.
268. Yang, H., Hoshino, K., Sanchez Gonzalez, B., Kantarjian, H., Garcia Manero, G., Antileukemia activity of the combination of 5-aza-2’-deoxycytidine with valproic acid. Leuk. Res. 29:29 (2005), 739–748.
269. Yang, X., Smith, S.L., Tian, X.C., Lewin, H.A., Renard, J.P., Wakayama, T., Nuclear reprogramming of cloned embryos and its implications for therapeutic cloning. Nat. Genet. 39 (2007), 295–302.
270. Yang, W., Chauhan, A., Mehta, S., Mehta, P., Gu, F., Chauhan, V., Trichostatin a increases the levels of plasma gelsolin and amyloid beta-protein in a transgenic mouse model of alzheimer's disease. Life Sci. 99:1 (2014), 31–36.
271. Yao, Y.X., Guan, W.J., Li, X.C., Su, X.H., Ma, Y.H., Li, H.P., Trichostatin A treatment on two types of donor cells for somatic cell nuclear transfer. J. Anim. Vet. Adv. 11 (2012), 1812–1818.
272. Yasuda, S., Liang, M.H., Marinova, Z., Yahyavi, A., Chuang, D.M., Themood stabilizers lithiumand valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 14 (2009), 51–59.
273. Yildirim, F., Gertz, K., Kronenberg, G., Harms, C., Fink, K.B., Meisel, A., Endres, M., Inhibition of histone deacetylation protects wildtype but not gelsolin -deficient mice from ischemic brain injury. Exp. Neurol. 210 (2008), 531–542.
274. Yoshida, M., Furumai, R., Nishiyama, M., Komatsu, Y., Nishino, N., Horinouchi, S., Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol., 48, 2001, S20.
275. Zhang, Z.Y., Schluesener, H.J., Oral administration of histone deacetylase inhibitor ms-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J. Neuropathol. Exp. Neurol. 72:3 (2013), 178–185.
276. Zhang, Z.Z., Qin, X.H., Tong, N., Zhao, X.F., Gong, Y.Y., Shi, Y., Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation. Exp. Eye Res. 94:1 (2011), 98–108.
277. Zhang, Z., Zhao, R., Qi, J., Wen, S., Tang, Y., Wang, D., Inhibition of glycogen synthase kinase-3β by Angelica sinensis extract decreases β-amyloid-induced neurotoxicity and τ phosphorylation in cultured cortical neurons. J. Neurosci. Res. 89 (2011), 437–447.
278. Zhang, H., Xiao, Y., Wang, X., Riaz, H., Li, W., Fu, S., Xin, Y., Shi, L., Ma, F., Li, X., Yang, L., Effects of histone deacetylase inhibitors on the early development of bovine androgenetic embryos. Cell. Reprogram. 16 (2014), 54–64.
279. Zhao, J., Ross, J.W., Hao, Y., Spate, L.D., Walters, E.M., Samuel, M.S., Rieke, A., Murphy, C.N., Prather, R.S., Significant improvement in cloning efficiency of an inbred miniature pig by histone deacetylase inhibitor treatment after somatic cell nuclear transfer. Biol. Reprod. 81 (2009), 525–530.
280. Zhao, T., Liu, X., Zhen, X., Guo, S.W., Levo-tetrahydropalmatine retards the growth of ectopic endometrial implants and alleviates generalized hyperalgesia in experimentally induced endometriosis in rats. Reprod. Sci. 18:1 (2011), 28–45.
281. Zheng, Z., Kim, J.Y., Ma, H., Lee, J.E., Yenari, M.A., Anti-inflammatory effects of the 70 kda heat shock protein in experimental stroke. J. Cereb. Blood Flow Metab. 28 (2008), 53–63.
282. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R., Timmusk, T., Sipione, S., Cattaneo, E., Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293 (2001), 493–498.